We focus on
KEEPING YOU UPDATED

Jul 15 2022

SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote

SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote

SERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment for ricin poisoning. There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available.